Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Bacterial Infections Suppress Immune Response in Neurodermatitis

November 20, 2014 9:31 am | by Technische Universität München | News | Comments

The skin condition neurodermatitis affects nearly one in four children and also occurs frequently in adults. Many patients also develop infections in the dry, open patches of skin, for example due to colonization by the pathogenic bacterium Staphylococcus aureus, which is particularly abundant on the skin of neurodermatitis patients. Read more...

TOPICS:

WHO: Ebola Transmission 'Intense' in Sierra Leone

November 20, 2014 9:24 am | by Clarence Roy-Macaulay - Associated Press | News | Comments

The spread of Ebola remains "intense" in most of Sierra Leone even as things have improved somewhat in the two other countries hardest hit, the World Health Organization says. Read more...                             

TOPICS:

Global Oncology Market to Hit $109B

November 20, 2014 9:19 am | News | Comments

Cancer, with a death toll exceeding that of AIDS (Acquired Immune Deficiency Syndrome), tuberculosis and malaria collectively, accounted for 8.3 million deaths in 2013. With a skyrocketing incidence of 469.6 per 100,000 in the US alone, the oncology market is poised to grow at a substantial CAGR of around 7% to $109 billion by 2020. Read more...

TOPICS:
Advertisement

Camurus, Braeburn Pharmaceuticals Sign Exclusive License for Opioid Treatment

November 20, 2014 9:15 am | News | Comments

Camurus and Braeburn Pharmaceuticals announced that they have entered into an exclusive license agreement for Camurus' weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain. Read more...   

TOPICS:

Regeneron, Sanofi: New Positive Results for Cholesterol-Lowering Drug

November 20, 2014 9:06 am | News | Comments

Regeneron Pharmaceuticals, Inc. and Sanofi announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Read more...

TOPICS:

Royalty Pharma Pays $3.3B for Cystic Fibrosis Royalties

November 19, 2014 1:51 pm | News | Comments

Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals' cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics' ("CFFT"), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion. Read more...

TOPICS:

HHS, NIH To Enhance Transparency of Clinical Trial Results

November 19, 2014 1:43 pm | News | Comments

The U.S. Department of Health and Human Services today issued a Notice of Proposed Rulemaking (NPRM), which proposes regulations to implement reporting requirements for clinical trials that are subject to Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Read more...

TOPICS:

$2.6B: Cost to Develop, Win Marketing Approval for New Drug

November 19, 2014 1:35 pm | News | Comments

Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to the Tufts Center for the Study of Drug Development. Read more...

TOPICS:
Advertisement

Chemical Disguise Transforms RNAi Drug Delivery

November 19, 2014 1:04 pm | News | Comments

Small pieces of synthetic RNA trigger a RNA interference (RNAi) response that holds great therapeutic potential to treat a number of diseases, especially cancer and pandemic viruses. The problem is delivery — it is extremely difficult to get RNAi drugs inside the cells in which they are needed.  Read more...

TOPICS:

Light-Responding Blood Vessel Receptor May Be New Target

November 19, 2014 12:46 pm | by Johns Hopkins | News | Comments

A team of researchers from Johns Hopkins Medicine has discovered a receptor on blood vessels that causes the vessel to relax in response to light, making it potentially useful in treating vascular diseases. In addition, researchers discovered a previously unknown mechanism by which blood vessel function is regulated through light of a specific wavelength. Read more...

TOPICS:

Maximizing the Power of Preclinical Cancer Research Tools

November 19, 2014 11:29 am | by Guizhong Liu, Senior Director of Cancer Biology, Crown Bioscience Inc. | Articles | Comments

Drug discovery is a protracted and uncertain process that needs to overcome many hurdles during preclinical and clinical development before it finally achieves regulatory approval for patient treatment. For every drug that reaches the marketplace, well over 100 have been abandoned at some point in their development. Read more...

TOPICS:

Janssen Seeks European Approval of Chronic Inflammatory Disease Drug

November 19, 2014 10:16 am | News | Comments

Janssen submitted an application for European approval regarding a drug intended to treat chronic inflammatory disease of the spine. Read more...                    

TOPICS:

Cardiome Finds Distributor for AFib Drug in South Africa

November 19, 2014 9:59 am | News | Comments

Cardiome entered into a new partnership with Pharmacare Ltd to sell and distribute its AFib drug in South Africa. Read more...                     

TOPICS:

New Laser Therapy Helps Slow Macular Degeneration

November 19, 2014 9:36 am | News | Comments

This new faster laser did not result in damage to the retina. Read more...                               

TOPICS:

Sub-Standard Meds Flood Afghan Market

November 19, 2014 9:24 am | News | Comments

Up to 300 companies in Pakistan produce poor quality drugs exclusively for Afghanistan because their products do not meet Pakistani government standards. Read more...                

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading